NEW YORK, November 8, 2025: Pfizer Inc. has agreed to acquire biotechnology company Metsera Inc. in a deal valued at approximately US $10 billion, concluding a competitive bidding contest that saw Novo Nordisk A/S withdraw its offer. The transaction ranks among the largest pharmaceutical acquisitions of the year, highlighting the growing importance of metabolic and obesity-related treatments in global healthcare markets. Under the terms of the agreement, Pfizer will pay Metsera shareholders US $65.60 per share in cash, along with contingent value rights of up to US $20.65 per share tied to the achievement of specific development milestones. The total potential value of the transaction is approximately US $86.25 per share.
The boards of both companies have approved the deal, which is expected to close following shareholder consent and standard regulatory reviews. Metsera, founded in 2022 and headquartered in the United States, develops next-generation therapies for obesity and metabolic disorders. Its portfolio includes a once-monthly injectable treatment designed to regulate appetite and metabolism, as well as an experimental amylin analog aimed at improving insulin sensitivity and weight management. The company has quickly become a focus of interest for major pharmaceutical groups seeking to expand in the metabolic disease market.
The acquisition follows a competitive process that began in late October when Novo Nordisk submitted an unsolicited bid for Metsera. Novo later raised its offer to nearly US $10 billion but faced concerns over regulatory exposure. Metsera’s board ultimately determined that Pfizer’s proposal provided greater certainty, given that it had already secured preliminary antitrust clearance from U.S. authorities. Novo Nordisk subsequently confirmed that it would not increase its offer and officially withdrew from the bidding process. Pfizer plans to finance the acquisition through a combination of existing cash reserves and short-term debt.
Metsera shareholders approve merger with Pfizer
The New York-based company said the purchase strengthens its portfolio in the field of metabolic and cardiovascular disease research. The transaction gives Pfizer immediate access to Metsera’s early-stage clinical and preclinical programs, which could support new treatment candidates over the coming years. The agreement extends a broader trend of consolidation within the pharmaceutical industry as large companies seek to replenish pipelines and strengthen their positions in high-growth therapeutic areas. The global market for obesity treatments has expanded rapidly, driven by advances in glucagon-like peptide (GLP-1) therapies and rising demand for effective long-term weight management options. Pfizer’s move to acquire Metsera provides it with new assets and research capabilities in a field projected to generate significant healthcare spending worldwide.
Novo Nordisk, based in Denmark, remains a leader in diabetes and obesity treatments with its established GLP-1 product portfolio. Following its withdrawal, the company stated it remains focused on progressing its research programs and exploring other growth opportunities within its therapeutic focus areas. Metsera shareholders are scheduled to vote on the merger proposal on November 13, 2025. Subject to approval and completion of regulatory processes, the transaction is expected to close shortly thereafter. Once finalized, Metsera will become a wholly owned subsidiary of Pfizer, with its employees joining Pfizer’s research and development organization.
Metsera adds value to Pfizer’s metabolic pipeline
The acquisition adds substantial value to Pfizer’s biotechnology portfolio and reinforces its commitment to advancing innovative therapies addressing global health challenges. Both companies indicated that integration planning is underway and that operations are expected to continue without disruption following the completion of the deal, ensuring continuity across research programs, regulatory commitments, and patient access initiatives throughout the transition period. Pfizer stated that it intends to retain Metsera’s core scientific and operational teams to preserve institutional expertise and accelerate ongoing clinical development, supporting long-term growth in metabolic and endocrine therapeutics. – By Content Syndication Services.